Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUMEX vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Edema associated with congestive heart failure,Edema associated with hepatic cirrhosis,Edema associated with renal disease including nephrotic syndrome
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (Cr Cl <20 m L/min).
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Bumetanide is 94–96% bound to plasma proteins (primarily albumin).
Approximately 95% bound, primarily to albumin.
0.15–0.22 L/kg; indicates primarily extracellular distribution.
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Oral bioavailability: 80–100% (mean ~95%).
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
e GFR <20 m L/min/1.73 m²: Avoid loop diuretics; consider alternative. No adjustment for mild to moderate renal impairment, but monitor response. In severe renal failure, may require higher doses due to reduced tubular secretion.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Child-Pugh Class B or C: Reduce initial dose by 50% due to impaired metabolism and increased risk of volume depletion. Titrate cautiously.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Infants/Children: Oral: 0.015-0.1 mg/kg/dose once daily; maximum 10 mg/day. IV/IM: 0.015-0.1 mg/kg/dose every 12-24 hours; maximum 0.5 mg/kg/dose. Neonates: 0.01-0.05 mg/kg/dose every 24-48 hours.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Start at 0.5 mg orally once daily; increase cautiously due to enhanced pharmacodynamic effects and higher risk of electrolyte disturbances, volume depletion, and ototoxicity. Monitor renal function and electrolytes closely.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Bumetanide is a potent diuretic; if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule must be adjusted to individual patient's needs.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypovolemia,Ototoxicity (especially with rapid injection or in renal impairment),Excessive diuresis causing hypotension and thromboembolic events,May increase serum uric acid levels and precipitate gout,Risk of hypokalemia in patients with cirrhosis and ascites
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Anuria,Hepatic coma or severe electrolyte depletion until condition is corrected,Hypersensitivity to bumetanide or sulfonamides (cross-sensitivity possible)
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Avoid excessive salt intake; no specific food interactions reported. Avoid licorice as it may worsen hypokalemia. Grapefruit juice may increase bumetanide levels; use caution.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are limited; no well-controlled studies exist. First trimester: theoretical risk based on animal data; avoid unless essential. Second/third trimesters: may cause maternal hypovolemia, decreased placental perfusion, and fetal oliguria; use only if clearly needed and monitor amniotic fluid volume. Neonatal risks include electrolyte imbalances and ototoxicity if used close to delivery.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Bumetanide is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05-0.10. Based on limited data, amounts ingested by breastfed infants are unlikely to cause adverse effects. However, due to potential risk of hypersensitivity, electrolyte disturbances, or diuresis in the infant, caution is advised, especially in premature or renal-impaired infants. Alternative diuretics with more safety data may be preferred.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Pregnancy may alter bumetanide pharmacokinetics due to increased plasma volume, renal blood flow, and glomerular filtration rate. Higher doses may be required to achieve the same diuretic effect. However, no standard dose adjustment guidelines exist; use the lowest effective dose and titrate based on clinical response, monitoring for electrolyte disturbances and volume depletion. In severe preeclampsia or renal impairment, dose may need reduction. Close therapeutic drug monitoring is not routinely available; clinical monitoring of diuresis and electrolytes guides dosing.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
Bumetanide is a loop diuretic approximately 40 times more potent than furosemide; onset of diuresis within 30-60 minutes after oral administration. Monitor for ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Hypokalemia is a common adverse effect; consider potassium supplementation or concurrent use of potassium-sparing diuretics. Contraindicated in anuria, hepatic coma, and severe electrolyte depletion. May cause hyperuricemia and precipitate gout attacks.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Take this medication exactly as prescribed, typically once daily in the morning to avoid nighttime urination.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Do not consume grapefruit juice or alcohol while taking this drug.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or confusion.,Weigh yourself daily and report rapid weight gain or loss to your healthcare provider.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUMEX vs BUMETANIDE, answered by our medical review team.
BUMEX is a Loop Diuretic that works by Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUMEX and BUMETANIDE depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUMEX is: 0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUMEX and BUMETANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUMEX is classified as Category C. Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are l. BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.